Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice. 2023

Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, People's Republic of China.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by alveolar epithelial cell injury and lung fibroblast overactivation. At present, only two drugs are approved by the FDA for the treatment of IPF, including the synthetic pyridinone drug, pirfenidone, and the tyrosine kinase inhibitor, nintedanib. Avitinib (AVB) is a novel oral and potent third-generation tyrosine kinase inhibitor for treating non-small cell lung cancer (NSCLC). However, the role of avitinib in pulmonary fibrosis has not yet been established. In the present study, we used in vivo and in vitro models to evaluate the role of avitinib in pulmonary fibrosis. In vivo experiments first verified that avitinib significantly alleviated bleomycin-induced pulmonary fibrosis in mice. Further in vitro molecular studies indicated that avitinib inhibited myofibroblast activation, migration and extracellular matrix (ECM) production in NIH-3T3 cells, mainly by inhibiting the TGF-β1/Smad3 signalling pathways. The cellular experiments also indicated that avitinib improved alveolar epithelial cell injury in A549 cells. In conclusion, the present findings demonstrated that avitinib attenuates bleomycin-induced pulmonary fibrosis in mice by inhibiting alveolar epithelial cell injury and myofibroblast activation.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP

Related Publications

Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
January 2022, Frontiers in pharmacology,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
January 2019, Frontiers in pharmacology,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
January 2013, The journal of medical investigation : JMI,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
June 2005, American journal of respiratory and critical care medicine,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
October 2013, American journal of respiratory cell and molecular biology,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
June 1980, The Journal of pharmacology and experimental therapeutics,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
September 2023, Life (Basel, Switzerland),
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
December 2021, International journal of molecular sciences,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
July 2001, Chest,
Yang Miao, and Yanhua Wang, and Zhun Bi, and Kai Huang, and Jingjing Gao, and Xiaohe Li, and Shimeng Li, and Luqing Wei, and Honggang Zhou, and Cheng Yang
January 2015, Growth factors (Chur, Switzerland),
Copied contents to your clipboard!